CNSP

CNS Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website cnspharma.com
Employees(FY) 3
ISIN US18978H2013

Performance

+3.83%

1W

+4.08%

1M

-23.86%

3M

-89.67%

6M

-82.91%

YTD

-83.05%

1Y

Profile

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Advanced Technical Analysis

Technical Analysis of CNSP 2024-05-10

Overview:

In analyzing the technical indicators for CNSP over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key indicators, we aim to offer valuable insights and predictions for the upcoming days.

Trend Analysi...

See more ...

Recent News & Updates

2024-05-15 23:53
CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q1 2024(Investorplace)
2024-05-15 19:45
CNS Pharmaceuticals Reports First Quarter 2024 Financial Results(Accesswire)
2024-04-22 21:00
CNS Pharmaceuticals to Present at the LSX World Congress 2024(Accesswire)
2024-04-21 22:15
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity(Accesswire)
2024-04-01 11:52
CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q4 2023(Investorplace)
2024-04-01 05:00
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements(Accesswire)
2024-03-31 21:05
CNS Pharmaceuticals to Present at Two Investor Conferences in April(Accesswire)
2024-01-29 08:00
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering(Accesswire)
2024-01-17 19:45
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors(Accesswire)
2024-01-16 19:45
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)(Accesswire)
2023-12-17 19:35
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin(Accesswire)
2023-12-05 20:00
How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure(Accesswire)
2023-11-21 20:05
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy(Accesswire)
2023-11-15 21:00
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate(Accesswire)
2023-11-14 19:00
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End(Accesswire)
2023-10-18 21:05
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference(Accesswire)
2023-10-17 22:00
JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023(Accesswire)
2023-10-15 21:00
Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals Innovative Approach To Treatment Could Offer Hope(Accesswire)
2023-10-10 20:45
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date(Accesswire)
2023-09-06 20:45
CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)(Yahoo Finance)
2023-09-04 20:45
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-13 20:35
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy(Yahoo Finance)
2023-08-13 19:35
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones(Yahoo Finance)
2023-08-02 20:15
CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference(Yahoo Finance)
2023-08-02 20:00
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)(Yahoo Finance)
2023-07-26 21:05
CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference(Yahoo Finance)
2023-07-04 20:45
CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series(Yahoo Finance)
2023-06-13 21:05
CNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest(Yahoo Finance)
2023-05-24 21:05
CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)(Yahoo Finance)
2023-05-14 20:35
CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update(Yahoo Finance)

Page 1 of 4

previousnext